| __timestamp | Bio-Techne Corporation | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 122000 |
| Thursday, January 1, 2015 | 144969000 | 1896000 |
| Friday, January 1, 2016 | 162364000 | 2699000 |
| Sunday, January 1, 2017 | 188462000 | 1702000 |
| Monday, January 1, 2018 | 210850000 | 471000 |
| Tuesday, January 1, 2019 | 240515000 | 4101000 |
| Wednesday, January 1, 2020 | 255497000 | 1676000 |
| Friday, January 1, 2021 | 298182000 | 7264000 |
| Saturday, January 1, 2022 | 349103000 | 6594000 |
| Sunday, January 1, 2023 | 366887000 | 4661000 |
| Monday, January 1, 2024 | 389335000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis focuses on Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc., two prominent players in the field. Over the past decade, Bio-Techne has seen a consistent rise in its cost of revenue, growing by approximately 266% from 2014 to 2023. This trend reflects the company's expanding operations and increased production capabilities.
Conversely, BioCryst Pharmaceuticals has experienced more volatility. While its cost of revenue surged by over 5,800% from 2014 to 2021, it has since shown a decline, indicating potential shifts in production strategies or market conditions. Notably, data for 2024 is missing, suggesting a need for further investigation into recent developments.
These insights provide a window into the financial dynamics of biotech firms, highlighting the importance of cost management in sustaining growth.
Cost Insights: Breaking Down Eli Lilly and Company and Bio-Techne Corporation's Expenses
Cost of Revenue: Key Insights for Johnson & Johnson and BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and Bio-Techne Corporation's Expenses
Cost of Revenue Comparison: GSK plc vs BioCryst Pharmaceuticals, Inc.
Insmed Incorporated vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Bio-Techne Corporation vs Grifols, S.A.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Bausch Health Companies Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Mesoblast Limited
Cost of Revenue: Key Insights for Bio-Techne Corporation and Taro Pharmaceutical Industries Ltd.
BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Ligand Pharmaceuticals Incorporated and BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: BioCryst Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.